Black Diamond Therapeutics (BDTX) Notes Payables (2018 - 2020)
Black Diamond Therapeutics' (BDTX) quarterly Notes Payables came in at $190000.0 in Q3 2020, up 1166.67% quarter-over-quarter from $15000.0 in Q2 2020.
Powered by 
Analysis
Black Diamond Therapeutics (BDTX) Notes Payables (2018 - 2020) Analysis & Trends
Black Diamond Therapeutics (BDTX) has reported Notes Payables for 2 consecutive years, with $190000.0 the latest figure, recorded in Q3 2020.
- For the quarter ending Q3 2020, Notes Payables changed N/A year-over-year to $190000.0; the trailing twelve-month figure through Sep 2020 stood at $190000.0 (changed N/A YoY), and the FY2018 full-year result was $1.7 million, changed N/A from the prior year.
- Notes Payables climbed to $190000.0 in Q3 2020 per BDTX's latest filing, from $15000.0 in the prior quarter.
- Across five years, Notes Payables topped out at $1.7 million in Q4 2018 and bottomed at $15000.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Black Diamond Therapeutics | 111.58 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 190,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Mar 31, 2020 | 964,000.00 |
| Dec 31, 2018 | 1.71 Mn |